340 related articles for article (PubMed ID: 9170438)
1. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
Zhu H; Baxter LT; Jain RK
J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
[TBL] [Abstract][Full Text] [Related]
2. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
3. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
6. Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment.
Kamigaki T; Yamamoto M; Ohyanagi H; Ohya M; Shimazoe T; Kono A; Ohtani W; Narita Y; Ohkubo M; Saitoh Y
Jpn J Cancer Res; 1995 Dec; 86(12):1216-23. PubMed ID: 8636013
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha-2b immunoconjugate for improving immunoscintigraphy and immunotherapy.
Pallela VR; Rao SP; Thakur ML
J Nucl Med; 2000 Jun; 41(6):1108-13. PubMed ID: 10855643
[TBL] [Abstract][Full Text] [Related]
8. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
Sharkey RM; Goldenberg DM; Vagg R; Pawlyk D; Wong GY; Siegel JA; Murthy S; Levine GM; Izon D; Gascon P
Cancer; 1994 Feb; 73(3 Suppl):864-77. PubMed ID: 8306272
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
11. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
[TBL] [Abstract][Full Text] [Related]
16. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
17. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.
Buchegger F; Allal AS; Roth A; Papazyan JP; Dupertuis Y; Mirimanoff RO; Gillet M; Pelegrin A; Mach JP; Slosman DO
Anticancer Res; 2000; 20(3B):1889-96. PubMed ID: 10928122
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.
Ugur O; Kostakoglu L; Hui ET; Fisher DR; Garmestani K; Gansow OA; Cheung NK; Larson SM
Nucl Med Biol; 1996 Jan; 23(1):1-8. PubMed ID: 9004907
[TBL] [Abstract][Full Text] [Related]
19. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
20. Differences in biodistribution of the anti-(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.
Westera G; Rülicke T; Smith A; Duewell S
Cancer Immunol Immunother; 1994 Dec; 39(6):375-82. PubMed ID: 8001025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
